AstraZeneca's Gout Dilemma: Should Smaller, More Frequent Lesinurad Dose Be Studied?
Executive Summary
FDA is concerned about product's narrow therapeutic index, but advisory committee says it’s not an issue for approval; could this be addressed in post-marketing trial?